These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 19666597)
21. Studies on the biosynthesis of the lipodepsipeptide antibiotic Ramoplanin A2. Hoertz AJ; Hamburger JB; Gooden DM; Bednar MM; McCafferty DG Bioorg Med Chem; 2012 Jan; 20(2):859-65. PubMed ID: 22222159 [TBL] [Abstract][Full Text] [Related]
22. Structure elucidation and 3D solution conformation of the antibiotic enduracidin determined by NMR spectroscopy and molecular dynamics. Castiglione F; Marazzi A; Meli M; Colombo G Magn Reson Chem; 2005 Aug; 43(8):603-10. PubMed ID: 15986494 [TBL] [Abstract][Full Text] [Related]
23. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci. Lawrence T; Rotstein C; Beam TR; Gorzynski EA; Amsterdam D Antimicrob Agents Chemother; 1993 Apr; 37(4):896-900. PubMed ID: 8494388 [TBL] [Abstract][Full Text] [Related]
24. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Reynolds PE; Somner EA Drugs Exp Clin Res; 1990; 16(8):385-9. PubMed ID: 2151441 [TBL] [Abstract][Full Text] [Related]
26. Lipid II as a target for antibiotics. Breukink E; de Kruijff B Nat Rev Drug Discov; 2006 Apr; 5(4):321-32. PubMed ID: 16531990 [TBL] [Abstract][Full Text] [Related]
27. Teixobactin kills bacteria by a two-pronged attack on the cell envelope. Shukla R; Lavore F; Maity S; Derks MGN; Jones CR; Vermeulen BJA; Melcrová A; Morris MA; Becker LM; Wang X; Kumar R; Medeiros-Silva J; van Beekveld RAM; Bonvin AMJJ; Lorent JH; Lelli M; Nowick JS; MacGillavry HD; Peoples AJ; Spoering AL; Ling LL; Hughes DE; Roos WH; Breukink E; Lewis K; Weingarth M Nature; 2022 Aug; 608(7922):390-396. PubMed ID: 35922513 [TBL] [Abstract][Full Text] [Related]
28. Production of Ramoplanin and Ramoplanin Analogs by Actinomycetes. de la Cruz M; González I; Parish CA; Onishi R; Tormo JR; Martín J; Peláez F; Zink D; El Aouad N; Reyes F; Genilloud O; Vicente F Front Microbiol; 2017; 8():343. PubMed ID: 28321210 [TBL] [Abstract][Full Text] [Related]
29. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341 [TBL] [Abstract][Full Text] [Related]
30. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492 [TBL] [Abstract][Full Text] [Related]
31. Ramoplanin: a lipoglycodepsipeptide antibiotic. Farver DK; Hedge DD; Lee SC Ann Pharmacother; 2005 May; 39(5):863-8. PubMed ID: 15784805 [TBL] [Abstract][Full Text] [Related]
32. Multiple attack on bacteria by the new antibiotic teixobactin. von Nussbaum F; Süssmuth RD Angew Chem Int Ed Engl; 2015 Jun; 54(23):6684-6. PubMed ID: 25968231 [No Abstract] [Full Text] [Related]
33. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Peláez T; Alcalá L; Alonso R; Martín-López A; García-Arias V; Marín M; Bouza E Antimicrob Agents Chemother; 2005 Mar; 49(3):1157-9. PubMed ID: 15728918 [TBL] [Abstract][Full Text] [Related]
34. X-ray crystallographic structure of a teixobactin analogue reveals key interactions of the teixobactin pharmacophore. Yang H; Du Bois DR; Ziller JW; Nowick JS Chem Commun (Camb); 2017 Feb; 53(18):2772-2775. PubMed ID: 28217800 [TBL] [Abstract][Full Text] [Related]
35. Substrate analogues to study cell-wall biosynthesis and its inhibition. Lazar K; Walker S Curr Opin Chem Biol; 2002 Dec; 6(6):786-93. PubMed ID: 12470732 [TBL] [Abstract][Full Text] [Related]
36. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients. Rolston KV; Dholakia N; Ho DH; LeBlanc B; Dvorak T; Streeter H J Antimicrob Chemother; 1996 Aug; 38(2):265-9. PubMed ID: 8877541 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium. Ristow TA; Noskin GA; Warren JR; Peterson LR Microb Drug Resist; 1995; 1(4):335-9. PubMed ID: 9158806 [TBL] [Abstract][Full Text] [Related]
38. Treatment of experimental endocarditis caused by multidrug resistant Enterococcus faecium with ramoplanin and penicillin. Landman D; Quale JM; Burney S; Kreiswirth B; Willey BM J Antimicrob Chemother; 1996 Feb; 37(2):323-9. PubMed ID: 8707742 [TBL] [Abstract][Full Text] [Related]
39. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Johnson CC; Taylor S; Pitsakis P; May P; Levison ME Antimicrob Agents Chemother; 1992 Oct; 36(10):2342-5. PubMed ID: 1444316 [TBL] [Abstract][Full Text] [Related]
40. Lipophilic vancomycin aglycon dimer with high activity against vancomycin-resistant bacteria. Yarlagadda V; Sarkar P; Manjunath GB; Haldar J Bioorg Med Chem Lett; 2015 Dec; 25(23):5477-80. PubMed ID: 26525861 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]